Drug-like Annotation and Duplicate Analysis of a 23-Supplier Chemical Database Totalling 2.7 Million Compounds

Abstract

We have implemented five drug-like filters, based on 1D and 2D molecular descriptors, and applied them to characterize the drug-like properties of commercially available chemical compounds. In addition to previously published filters (Lipinski and Veber), we implemented a filter for medicinal chemistry tractability based on lists of chemical features drawn up by a panel of medicinal chemists. A filter based on the modeling of aqueous solubility (>1 microM) was derived in-house, as well as another based on the modeling of Caco-2 passive membrane permeability (>10 nm/s). A library of 2.7 million compounds was collated from the 23 compound suppliers and analyzed with these filters, highlighting a tendency toward highly lipophilic compounds. The library contains 1.6 M unique structures, of which 37% (607,223) passed all five drug-like filters. None of the 23 suppliers provides all the members of the drug-like subset, emphasizing the benefit of considering compounds from various compound suppliers as a source of diversity for drug discovery.

The identification of novel PLC-γ inhibitors using virtual high throughput screening

“…Commercial compound collections tend to be lipophilic 57 and it is important to eliminate these chemical species from the molecular candidates. We had some problems with compound insolubility but it was minimised by installing the Log P/S filters.…”

Benchmarking the Reliability of QikProp. Correlation between Experimental and Predicted Values

“…First introduced by Lipinski [1,2], and then further augmented by Veber et al [3], their rules not only influence decision making for synthetic purposes but are also important in the selection of molecules for screening libraries obtained from commercial providers. This is particularly important due to the tendency of commercial compound collections to be lipophilic [4]. It is essential to start with a reasonably hydrophilic compound for a drug development project because optimizing a hit compound to a drug candidate usually increases lipophilicity, as a consequence of affinity enhancement [5].…”

In Silico-In Vitro Screening of Protein-Protein Interactions: Towards the Next Generation of Therapeutics

“…Some of these libraries contain only marketed drugs and/or natural products while others are for cherry picking. Many of these collections have been analyzed in depth these last few years [184][185][186][187][188][189][190] (Table III). Virtual compound collections can also be generated with the risk that some molecules will not be possible to synthesize easily.…”